IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v44y1998i3p215-232.html
   My bibliography  Save this article

Economic evaluation of end stage renal disease treatment

Author

Listed:
  • de Wit, G.Ardine
  • Ramsteijn, Paul G
  • de Charro, Frank Th

Abstract

No abstract is available for this item.

Suggested Citation

  • de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    • Handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:215-232
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(98)00017-7
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. D.N. Churchill & B.C. Lemon & G.W. Torrance, 1984. "A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital Hemodialysis," Medical Decision Making, , vol. 4(4), pages 489-500, December.
    2. Norman F. Boyd & Heather J. Sutherland & Karen Z. Heasman & David L. Tritchler & Bernard J. Cummings, 1990. "Whose Utilities for Decision Analysis?," Medical Decision Making, , vol. 10(1), pages 58-67, February.
    3. J.Robert Beck & Stephen G. Pauker, 1983. "The Markov Process in Medical Prognosis," Medical Decision Making, , vol. 3(4), pages 419-458, December.
    4. David G. Simon, 1986. "A Cost-effectiveness Analysis of Cyclosporine in Cadaveric Kidney Transplantation," Medical Decision Making, , vol. 6(4), pages 199-207, December.
    5. Frank A. Sonnenberg & J. Robert Beck, 1993. "Markov Models in Medical Decision Making," Medical Decision Making, , vol. 13(4), pages 322-338, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sigrid M Mohnen & Manon J M van Oosten & Jeanine Los & Martijn J H Leegte & Kitty J Jager & Marc H Hemmelder & Susan J J Logtenberg & Vianda S Stel & Leona Hakkaart-van Roijen & G Ardine de Wit, 2019. "Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-14, August.
    2. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    3. Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    4. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    5. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
    6. Just, Paul Michael & Riella, Miguel Carlos & Tschosik, Elizabeth Ann & Noe, Leslie Lyle & Bhattacharyya, Samir Kumar & de Charro, Frank, 2008. "Economic evaluations of dialysis treatment modalities," Health Policy, Elsevier, vol. 86(2-3), pages 163-180, May.
    7. Afiatin & Levina Chandra Khoe & Erna Kristin & Lusiana Siti Masytoh & Eva Herlinawaty & Pitsaphun Werayingyong & Mardiati Nadjib & Sudigdo Sastroasmoro & Yot Teerawattananon, 2017. "Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-10, May.
    8. Gijs Van de Wetering & Willem H. Woertman & Eddy M. M. Adang, 2012. "A model to correct for short‐run inefficiencies in economic evaluations in healthcare," Health Economics, John Wiley & Sons, Ltd., vol. 21(3), pages 270-281, March.
    9. Thomas W Ferguson & James Zacharias & Simon R Walker & David Collister & Claudio Rigatto & Navdeep Tangri & Paul Komenda, 2015. "An Economic Assessment Model of Rural and Remote Satellite Hemodialysis Units," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-11, August.
    10. Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne, 2011. "A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease," PharmacoEconomics, Springer, vol. 29(10), pages 839-861, October.
    11. Charles Christian Adarkwah & Afschin Gandjour & Maren Akkerman & Silvia M Evers, 2011. "Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-10, October.
    12. Sergio Iannazzo & Michela Carsi & Silvia Chiroli, 2012. "A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries," Applied Health Economics and Health Policy, Springer, vol. 10(2), pages 127-138, March.
    13. Bernadette Li & John Cairns & James Fotheringham & Rommel Ravanan, 2016. "Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(6), pages 659-668, July.
    14. Peeters, Pascale & Rublee, Dale & Just, Paul M. & Joseph, Alain, 2000. "Analysis and interpretation of cost data in dialysis: review of Western European literature," Health Policy, Elsevier, vol. 54(3), pages 209-227, December.
    15. Steef Redeker & Sohal Ismail & Hester V. Eeren & Emma K. Massey & Willem Weimar & Mark Oppe & Jan Busschbach, 2022. "A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(4), pages 597-606, June.
    16. Mario Eandi & Lorenzo Pradelli & Sergio Iannazzo & Silvia Chiroli & Giuseppe Pontoriero, 2010. "Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy," PharmacoEconomics, Springer, vol. 28(11), pages 1041-1054, November.
    17. Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan, 2023. "A Systematic Review of Kidney Transplantation Decision Modelling Studies," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 39-51, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
    2. Gordon B. Hazen, 2022. "Augmenting Markov Cohort Analysis to Compute (Co)Variances: Implications for Strength of Cost-Effectiveness," INFORMS Journal on Computing, INFORMS, vol. 34(6), pages 3170-3180, November.
    3. Franck Maunoury & Anastasiia Motrunich & Maria Palka-Santini & Stéphanie F Bernatchez & Stéphane Ruckly & Jean-François Timsit, 2015. "Cost-Effectiveness Analysis of a Transparent Antimicrobial Dressing for Managing Central Venous and Arterial Catheters in Intensive Care Units," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    4. Rowan Iskandar, 2018. "A theoretical foundation for state-transition cohort models in health decision analysis," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-11, December.
    5. Franck Maunoury & Christian Farinetto & Stéphane Ruckly & Jeremy Guenezan & Jean-Christophe Lucet & Alain Lepape & Julien Pascal & Bertrand Souweine & Olivier Mimoz & Jean-François Timsit, 2018. "Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-16, May.
    6. Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter, 2009. "An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 111-119, February.
    7. Steven M. Shechter & Matthew D. Bailey & Andrew J. Schaefer & Mark S. Roberts, 2008. "The Optimal Time to Initiate HIV Therapy Under Ordered Health States," Operations Research, INFORMS, vol. 56(1), pages 20-33, February.
    8. Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson, 2006. "A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy," PharmacoEconomics, Springer, vol. 24(4), pages 387-400, April.
    9. Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol, 2005. "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 112-123, June.
    10. Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
    11. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
    12. Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
    13. Heß, Michael (Ed.) & Schlieter, Hannes (Ed.), 2014. "Modellierung im Gesundheitswesen: Tagungsband des Workshops im Rahmen der Modellierung 2014," ICB Research Reports 57, University Duisburg-Essen, Institute for Computer Science and Business Information Systems (ICB).
    14. Zixian, Liu & Xin, Ni & Yiliu, Liu & Qinglu, Song & Yukun, Wang, 2011. "Gastric esophageal surgery risk analysis with a fault tree and Markov integrated model," Reliability Engineering and System Safety, Elsevier, vol. 96(12), pages 1591-1600.
    15. Patricia Cubí‐Mollá & Mireia Jofre‐Bonet & Victoria Serra‐Sastre, 2017. "Adaptation to health states: Sick yet better off?," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1826-1843, December.
    16. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
    17. Karina Hansen & Christophe Lançon & Mondher Toumi, 2006. "Pharmacoeconomic modelling in schizophrenia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(1), pages 19-29, March.
    18. Peter A. Ubel & Jeff Richardson & Paul Menzel, 2000. "Societal value, the person trade‐off, and the dilemma of whose values to measure for cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 127-136, March.
    19. Malek B Hannouf & Chander Sehgal & Jeffrey Q Cao & Joseph D Mocanu & Eric Winquist & Gregory S Zaric, 2012. "Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
    20. Damschroder, Laura J. & Zikmund-Fisher, Brian J. & Ubel, Peter A., 2005. "The impact of considering adaptation in health state valuation," Social Science & Medicine, Elsevier, vol. 61(2), pages 267-277, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:44:y:1998:i:3:p:215-232. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.